Utrecht, 23 June 2026 Aalberts today reports that it has repurchased 8,000 of its own shares in the period from 15 June 2026, up and including 19 June 2026 for an amount of 319,903.12, so at an average share price of EUR 39.99. This is part of the share buyback programme as announced on 26 February 2026, for a total amount of EUR 75 million. The repurchase of shares commenced on 27 February 2026 and will be completed no later than 9 October 2026. It is intended that the shares will be cancelled following repurchase. Up to and including 19 June 2026, a cumulative total of 1,156,011 shares was repurchased under the share buyback programme for a total consideration of EUR 36,277,480. Aalberts has engaged an intermediary to repurchase the Aalberts shares in the open market, during open and closed periods, independent of Aalberts. The share...

Press Release June 23, 2026 Capital Markets Day 2026: Signify introduces strategy to create a more focused, better-performing company2029 medium-term objectives and updated capital allocation policy:Comparable sales growth of 0-1% Adjusted EBITA margin of c. 10% Free cash flow generation of 7-8% of sales Updated dividend policy to pay an annual cash dividend with a pay-out ratio of 40–50% of continuing net income*Eindhoven, The Netherlands – Signify (Euronext: LIGHT), the world leader in lighting, today introduces an updated strategy, portfolio priorities and medium-term financial objectives at its Capital Markets Day 2026. “Today, we are setting out a strategy to build a more focused, better-performing Signify. We are making deliberate portfolio choices and applying differentiated playbooks to drive a step-up in performance,...

June 23, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will host a webinar titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis” today, June 23, 2026, at 2:00pm ET. argenx management and scientific leadership will be joined by external key opinion leaders:Avery LaChance, MD, MPH, FAAD, Associate Professor of Dermatology, Harvard Medical School; Director of Connective Tissue Disease Clinic Arjun Seth, MD, Assistant Professor, Neurology (Neuromuscular Disease), Northwestern University Feinberg School of Medicine Rohit Aggarwal, MD, MS, Professor of Medicine, University of Pittsburgh, and Co-Director of UPMC Myositis CenterWebcast Information A live webcast...

Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapsesCenrifki represents a significant advancement for people living with SPMS by targeting disability progression Approval based on the HERCULES phase 3 study in nrSPMS with supporting data from the GEMINI 1 and 2 phase 3 studies in RMSParis, June 23, 2026. The European Commission has approved Cenrifki (tolebrutinib) for the treatment of secondary progressive multiple sclerosis (SPMS) without relapses in the last two years. This follows the positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use. The approval is based on results from the HERCULES phase 3 study (clinical study identifier: NCT04411641) in non-relapsing SPMS (nrSPMS), with...

Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopeniaWayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP) Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other symptoms ITP is a rare disease of complex immune dysregulation leading to lower platelet counts, bleeding, and reduced quality of lifeParis, June 23, 2026. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization to Wayrilz (rilzabrutinib), a novel oral reversible Bruton’s tyrosine kinase inhibitor (BTKi), for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who do not respond sufficiently to other treatments or in whom tolerability...

The shares in SalMar ASA will be quoted ex-dividend of NOK 10.00 per share as from today, 23 June 2026. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Opportunistic capital raise with proceeds used to enhance strategic flexibility to invest for future growth Approximately $290 million of the proceeds to be used to repurchase shares concurrently with the Offering Additionally, a portion of the proceeds to be used to purchase capped calls intended to offset any share dilution until a 125% premium to the last reported sale price of Robinhood’s Class A common stock on the date of pricing MENLO PARK, Calif., June 22, 2026 (GLOBE NEWSWIRE) — Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today announced that it has priced an offering of $2.0 billion in aggregate principal amount of 0.00% convertible senior notes due 2029 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities...

SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in 1×1 investor meetings at the Leerink Partners Therapeutics Forum in Boston, MA on July 15, 2026. Inducement Grant In connection with the hiring of two employees, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 34,300 stock options, in aggregate to purchase shares of the Company’s Series A common stock, be granted on June 22, 2026 to the newly hired employees. The option awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation...

MONTREAL, June 22, 2026 (GLOBE NEWSWIRE) — Stingray Group Inc. (TSX: RAY) (“Stingray” or the “Corporation”) wishes to advise that there will be a delay in the filing of its audited consolidated financial statements for the year ended March 31, 2026, management’s discussion and analysis thereof and the CEO and CFO certificates associated therewith (collectively, the “Required Disclosure”), which are due to be filed on or before June 29, 2026 (the “Filing Deadline”) pursuant to applicable securities laws. This delay is due to the fact that Stingray’s auditor has not completed the required work to conclude the audit. Stingray understands that the unanticipated delay in completing the audit of its consolidated financial statements for the year ended March 31, 2026 is in large part due to the complexity of integrating the acquisitions...